Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Yahoo10d
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
The primary objective of plozasiran treatment is to reduce APOC3 levels, thereby reducing triglycerides and helping to normalize lipid profiles. A total of 75 patients with genetically or ...
Hosted on MSN7mon
Plozasiran reduces triglyceride levels by 74% at 24 weeks
"Plozasiran produced significant reductions in triglyceride levels below the threshold associated with elevated risk for pancreatitis, with a favorable safety profile," said Daniel Gaudet, MD, Ph ...
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
Plozasiran specifically targets and reduce the production of APOC3, thereby reducing triglyceride levels and lowering the ...
Morningstar10d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025. “The NDA submission ...
Yahoo Finance10d
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
On 16 November, during the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, USA, findings from the Phase III PALISADE (NCT05089084) clinical trial of plozasiran ...
Nasdaq9d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
The NDA submission is supported by the SUMMIT program of clinical studies of plozasiran and positive findings in the Phase 3 PALISADE study. PALISADE successfully met its primary endpoint and all ...
Nasdaq10d
Arrowhead submits plozasiran NDA to FDA
Arrowhead (ARWR) announced that it submitted a new drug application, or NDA, to the FDA for investigational plozasiran for the treatment of familial chylomicronemia syndrome, or FCS, a severe and ...
Stockhouse10d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025. “The NDA submission for ...
FiercePharma23d
Arrowhead targets rare disease patients, pushing message that hope is on the horizon
The biotech is developing plozasiran, a siRNA candidate designed to silence APOC3, for the treatment of conditions including familial chylomicronemia syndrome (FCS). People with the rare genetic ...
Business Wire10d
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
“In the Phase 3 PALISADE study in patients with and without a genetic confirmation of familial chylomicronemia syndrome (FCS), plozasiran induced deep and sustained reductions in triglycerides ...